MX350009B - Derivados de 2-metoxi-piridin-4-ilo. - Google Patents
Derivados de 2-metoxi-piridin-4-ilo.Info
- Publication number
- MX350009B MX350009B MX2013007726A MX2013007726A MX350009B MX 350009 B MX350009 B MX 350009B MX 2013007726 A MX2013007726 A MX 2013007726A MX 2013007726 A MX2013007726 A MX 2013007726A MX 350009 B MX350009 B MX 350009B
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- pyridin
- methoxy
- formula
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2011050241 | 2011-01-19 | ||
| PCT/IB2012/050241 WO2012098505A1 (fr) | 2011-01-19 | 2012-01-18 | Dérivés de 2-methoxy-pyridin-4-yl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013007726A MX2013007726A (es) | 2013-08-09 |
| MX350009B true MX350009B (es) | 2017-08-23 |
Family
ID=45607310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013007726A MX350009B (es) | 2011-01-19 | 2012-01-18 | Derivados de 2-metoxi-piridin-4-ilo. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9133179B2 (fr) |
| EP (1) | EP2665720B1 (fr) |
| JP (1) | JP5859570B2 (fr) |
| KR (1) | KR101869120B1 (fr) |
| CN (1) | CN103313981B (fr) |
| AR (1) | AR084883A1 (fr) |
| AU (1) | AU2012208325B2 (fr) |
| BR (1) | BR112013017923B1 (fr) |
| CA (1) | CA2818470C (fr) |
| CL (1) | CL2013002056A1 (fr) |
| CY (1) | CY1116657T1 (fr) |
| DK (1) | DK2665720T3 (fr) |
| ES (1) | ES2544086T3 (fr) |
| HK (1) | HK1191645A1 (fr) |
| HR (1) | HRP20150919T1 (fr) |
| HU (1) | HUE026012T2 (fr) |
| IL (1) | IL227509A0 (fr) |
| MA (1) | MA34910B1 (fr) |
| MX (1) | MX350009B (fr) |
| MY (1) | MY163185A (fr) |
| PL (1) | PL2665720T3 (fr) |
| PT (1) | PT2665720E (fr) |
| SG (1) | SG191742A1 (fr) |
| SI (1) | SI2665720T1 (fr) |
| TW (1) | TWI546300B (fr) |
| UA (1) | UA109804C2 (fr) |
| WO (1) | WO2012098505A1 (fr) |
| ZA (1) | ZA201306193B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY173573A (en) | 2013-03-15 | 2020-02-04 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| JP6294872B2 (ja) | 2013-04-26 | 2018-03-14 | 国立大学法人京都大学 | 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物 |
| CN105760707B (zh) * | 2014-12-18 | 2018-07-31 | 中国科学院大连化学物理研究所 | 细胞基因翻译过程建模方法 |
| AU2016263472B2 (en) | 2015-05-20 | 2020-02-27 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| CN107382965A (zh) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| WO1991015583A1 (fr) | 1990-04-05 | 1991-10-17 | The American National Red Cross | Famille de proteines apparentee a une proteine precoce immediate exprimee par des cellules endotheliales humaines durant la differenciation |
| AU653957B2 (en) | 1990-09-20 | 1994-10-20 | Merrell Dow Pharmaceuticals Inc. | 1-aryl-3-pyridinyl-2-propene-1-ones |
| DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
| JP2002505868A (ja) | 1998-03-09 | 2002-02-26 | スミスクライン・ビーチャム・コーポレイション | ヒトＥＤＧ−１ｃポリヌクレオチドおよびポリペプチドおよびその使用法 |
| DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| ES2250177T3 (es) | 1999-08-19 | 2006-04-16 | Nps Pharmaceuticals, Inc. | Compuestos heteropoliciclicos y su uso como antagonistas de receptores de glutamato metabotropico. |
| IL157491A0 (en) | 2001-02-21 | 2004-03-28 | Nps Pharmeceuticals Inc | Heteropolycyclic compounds and pharmaceutical compositions containing the same |
| EP1470137B1 (fr) | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Agonistes du recepteur edg |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| US7199142B2 (en) | 2002-06-17 | 2007-04-03 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists |
| DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| EP1625123A4 (fr) * | 2003-05-15 | 2007-08-29 | Merck & Co Inc | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles servant d'agonistes du recepteur s1p |
| WO2005014525A2 (fr) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Compose bi-aryle presentant une activite immunosuppressive |
| CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| JP4773972B2 (ja) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸 |
| KR20070045153A (ko) | 2004-05-29 | 2007-05-02 | 7티엠 파마 에이/에스 | 의약용 씨알티에이치2 수용체 리간드 |
| WO2006010379A1 (fr) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Nouveaux derives du thiophene utilises comme agents immunosupresseurs |
| US7659294B2 (en) | 2004-10-22 | 2010-02-09 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| KR101262400B1 (ko) | 2004-12-13 | 2013-05-08 | 오노 야꾸힝 고교 가부시키가이샤 | 아미노카르복실산 유도체 및 그 의약 용도 |
| SI1863474T1 (sl) | 2005-03-23 | 2009-04-30 | Actelion Pharmaceuticals Ltd | Novi derivati tiofena kot agonisti receptorja sfingozin-1-fosfat-1 |
| SI1863787T1 (sl) | 2005-03-23 | 2011-10-28 | Actelion Pharmaceuticals Ltd | Hidrogenirani benzo(c)tiofenski derivati kot imunomodulatorji |
| JP5063581B2 (ja) | 2005-03-23 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規チオフェン誘導体 |
| CA2604161A1 (fr) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Derives de purine et d'imidazopyridine en vue d'une immunosuppression |
| JPWO2006115188A1 (ja) | 2005-04-22 | 2008-12-18 | 第一三共株式会社 | ヘテロ環化合物 |
| MX2007013263A (es) | 2005-04-26 | 2008-01-22 | Neurosearch As | Novedosos derivados oxadiazol y su uso medico. |
| AU2006256968A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands |
| US20070043104A1 (en) | 2005-06-10 | 2007-02-22 | Luthman Ingrid K | UII-modulating compounds and their use |
| AU2006260573A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| WO2007001973A1 (fr) | 2005-06-28 | 2007-01-04 | Astrazeneca Ab | Utilisation |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| EP1979345B1 (fr) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Nouveaux dérivés de pyridine |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| EP1991535A1 (fr) | 2006-02-21 | 2008-11-19 | University Of Virginia Patent Foundation | Composés de phényl-cycloalkyl contenant des structures à anneau hétérocyclique |
| MX2008013990A (es) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Derivados de cicloalquilamino acidos. |
| PT2069336E (pt) * | 2006-09-07 | 2013-03-07 | Actelion Pharmaceuticals Ltd | Derivados de piridin-4-ilo como agentes imunomoduladores |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| US8288554B2 (en) | 2006-09-08 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyridin-3-yl derivatives as immunomodulating agents |
| JP5250556B2 (ja) | 2006-09-21 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | フェニル誘導体及びそれらの免疫調節薬としての使用 |
| KR20090057070A (ko) | 2006-09-29 | 2009-06-03 | 노파르티스 아게 | 소염성 및 면역억제성을 갖는 옥사디아졸 유도체 |
| JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| WO2008091967A1 (fr) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Composés chimiques |
| WO2008114157A1 (fr) | 2007-03-16 | 2008-09-25 | Actelion Pharmaceuticals Ltd | Dérivés d'amino-pyridine comme agonistes du récepteur s1p1/edg1 |
| PL2195311T3 (pl) | 2007-08-17 | 2011-08-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
| WO2009043890A1 (fr) | 2007-10-04 | 2009-04-09 | Merck Serono S.A. | Composés oxadiazole diarylés |
| MX2010003612A (es) | 2007-10-04 | 2010-04-30 | Merck Serono Sa | Derivados de oxadiazol. |
| BRPI0818804A2 (pt) | 2007-11-01 | 2015-04-22 | Actelion Pharmaceuticals Ltd | Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. |
| JP2011503046A (ja) | 2007-11-08 | 2011-01-27 | ファイザー・インク | シクロブチルカルボン酸誘導体 |
| RU2010128006A (ru) | 2007-12-10 | 2012-01-20 | Актелион Фармасьютиклз Лтд (Ch) | Производные тиофена в качестве агонистов sipi/edgi |
| EP2222668B1 (fr) * | 2007-12-18 | 2011-11-02 | Arena Pharmaceuticals, Inc. | Dérivés d'acide tétrahydrocyclopenta[b]indol-3-ylcarboxylique utiles dans le traitement de troubles auto-immuns et inflammatoires |
| EP2262799B1 (fr) | 2008-03-06 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Composés de pyridine |
| EP2262800A1 (fr) | 2008-03-06 | 2010-12-22 | Actelion Pharmaceuticals Ltd. | Nouveaux dérivés de pyrimidine-pyridine |
| ES2414533T3 (es) | 2008-03-07 | 2013-07-19 | Actelion Pharmaceuticals Ltd. | Derivados Piridin-2-ilo como agentes inmunomoduladores |
| BRPI0910288A2 (pt) * | 2008-03-07 | 2019-09-24 | Actelion Pharmaceuticals Ltd | composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo. |
| NZ589617A (en) | 2008-05-14 | 2012-06-29 | Scripps Research Inst | 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives |
| US20120101134A1 (en) | 2009-06-26 | 2012-04-26 | Glaxo Group Limited | 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists |
| TWI410421B (zh) * | 2009-07-16 | 2013-10-01 | Actelion Pharmaceuticals Ltd | 吡啶－４－基衍生物 |
-
2012
- 2012-01-18 AU AU2012208325A patent/AU2012208325B2/en not_active Ceased
- 2012-01-18 ES ES12704125.9T patent/ES2544086T3/es active Active
- 2012-01-18 WO PCT/IB2012/050241 patent/WO2012098505A1/fr active Application Filing
- 2012-01-18 SI SI201230254T patent/SI2665720T1/sl unknown
- 2012-01-18 JP JP2013549917A patent/JP5859570B2/ja active Active
- 2012-01-18 AR ARP120100163A patent/AR084883A1/es unknown
- 2012-01-18 KR KR1020137020321A patent/KR101869120B1/ko active IP Right Grant
- 2012-01-18 UA UAA201309611A patent/UA109804C2/ru unknown
- 2012-01-18 MA MA36184A patent/MA34910B1/fr unknown
- 2012-01-18 CA CA2818470A patent/CA2818470C/fr active Active
- 2012-01-18 US US13/980,764 patent/US9133179B2/en active Active
- 2012-01-18 MY MYPI2013701260A patent/MY163185A/en unknown
- 2012-01-18 SG SG2013047212A patent/SG191742A1/en unknown
- 2012-01-18 EP EP12704125.9A patent/EP2665720B1/fr active Active
- 2012-01-18 HU HUE12704125A patent/HUE026012T2/en unknown
- 2012-01-18 PL PL12704125T patent/PL2665720T3/pl unknown
- 2012-01-18 TW TW101101997A patent/TWI546300B/zh active
- 2012-01-18 BR BR112013017923-6A patent/BR112013017923B1/pt active IP Right Grant
- 2012-01-18 PT PT127041259T patent/PT2665720E/pt unknown
- 2012-01-18 MX MX2013007726A patent/MX350009B/es active IP Right Grant
- 2012-01-18 CN CN201280005493.7A patent/CN103313981B/zh active Active
- 2012-01-18 DK DK12704125.9T patent/DK2665720T3/en active
-
2013
- 2013-07-17 CL CL2013002056A patent/CL2013002056A1/es unknown
- 2013-07-17 IL IL227509A patent/IL227509A0/en active IP Right Grant
- 2013-08-16 ZA ZA2013/06193A patent/ZA201306193B/en unknown
-
2014
- 2014-05-23 HK HK14104850.5A patent/HK1191645A1/xx not_active IP Right Cessation
-
2015
- 2015-08-28 CY CY20151100762T patent/CY1116657T1/el unknown
- 2015-09-02 HR HRP20150919TT patent/HRP20150919T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY153617A (en) | Pyridin-4-yl derivatives | |
| PH12015501412A1 (en) | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| MY170878A (en) | [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| PH12015501083B1 (en) | Novel pyridine derivatives | |
| MY183039A (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
| MY150661A (en) | Pyridin-3-yl derivatives as immunomodulating agents | |
| PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
| MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
| MX346248B (es) | Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2. | |
| TW200942524A (en) | Novel aminomethyl benzene derivatives | |
| TW200942530A (en) | Pyridine compounds | |
| PH12014501415A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists | |
| MX2014004920A (es) | Nuevos derivados de pirazina. | |
| PH12015502409A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists | |
| MX340574B (es) | Imidazo pirazinas. | |
| WO2014062838A3 (fr) | Modulateurs de pkm2 et procédés pour les utiliser | |
| MY163185A (en) | 2-methoxy-pyridin-4-yl derivatives | |
| IN2014DN10669A (fr) | ||
| PH12015500399A1 (en) | Azaindolines | |
| AU2013314244A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
| MX345264B (es) | Derivado de azol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: IDORSIA PHARMACEUTICALS LTD |